Gritstone bio to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 9, 2023

On March 2, 2023 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, reported its fourth quarter and full year 2022 financial results and provide a corporate update following market close on Thursday, March 9, 2023 (Press release, Gritstone Bio, MAR 2, 2023, View Source [SID1234628056]). The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access by webcast, visit: View Source
To access by phone, dial: 1-877-407-4018
Conference ID: 13734754

While not required, it is recommended you join five minutes prior to the event’s start. An archived replay will be accessible at View Source for 30 days following the event.